ClinicalTrials.gg
Not yet recruitingNCT07886476Updated Oct 21, 2026

IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy

A Phase 1 interventional study of IBI3034 and Placebo in IgA Nephropathy (IgAN), sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Updated Oct 21, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
45th of 109
100 · median 84
Started
2026
with 24 others
Phase 1
21 of 127
13 open now
Primary completion
2027-01
later than 28 of 72 live
Registered
123rd of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 45th largest by planned enrollment of the 109 interventional ones that give a count, is one of 25 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 28 of the 72 other live ones, and was the 123rd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study

Read the detailed description

A double-blind design is applied to the IBI3034 and placebo groups in both Part 1 and Part 2; the Telitacicept positive control group is open-label Part 1: A randomized, double-blind, single-center, single-dose, dose-escalation, placebo-controlled study. Healthy participants will be randomized to receive IBI3034 or placebo in a 3:1 ratio. Part 2: A randomized, double-blind, multiple-dose, dose-escalation, placebo-controlled study. Participants will be randomized in an 8:2:2 ratio to receive IBI3034, placebo, or Telitacicept.

03

Conditions studied

  • IgA Nephropathy (IgAN)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion (Part 1 - Healthy):

  1. Understand and voluntarily sign the form (ICF).
  2. Male or female, aged 18 to 45 years (inclusive).
  3. Body weight of 50 to 120 kg, of 18.0 to 28.0 kg/m².
  4. Males and females of must agree to use highly effective and refrain from donating sperm/ova for 6 months after the last dose.

Inclusion (Part 2 - IgAN)

  1. Understand and voluntarily sign the informed consent form (ICF).
  2. Male or female, aged 18 to 65 years (inclusive).
  3. -confirmed primary IgA nephropathy without known secondary causes within 10 years prior to screening.
  4. Persistent proteinuria at screening: 24h-UPCR ≥ 0.75 g/g or 24h-UPE ≥ 1.0 g/24h.
  5. ≥ 45 mL/min/1.73 m² at screening (CKD-EPI 2021 equation).
  6. Receiving stable and optimized supportive therapy (ACEI and/or ARB ≥ 12 weeks, stable dose ≥ 4 weeks prior to randomization).
  7. Participants of childbearing potential must agree to use highly effective contraception and refrain from donating sperm/ova for 6 months after the last dose.

Exclusion (Both Parts)

  • 1. Known to any component of IBI3034 or history of severe allergic reactions.

    2. Inability to tolerate subcutaneous injections. 3. Vaccination with a within 30 days prior to randomization. 4. Blood donation or blood loss ≥ 400 mL within 3 months prior to screening. 5. Positive serological test for -Ab, Treponema pallidum antibody, -Ab, or any -related markers.

    6. History of disseminated herpes zoster or recurrent localized dermatomal herpes zoster.

    7. Known active tuberculosis or positive IGRA. 8. Concurrent or lymphoproliferative disease. 9. Immunodeficiency disorders. 10. Severe infection or surgery requiring hospitalization within 6 months prior to randomization.

    11. Pregnant or lactating females. 12. History of drug abuse within 12 months prior to screening. 13. Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.

Part 2 Specific Exclusions

  1. Participation in another drug or medical device clinical trial within 90 days prior to randomization.
  2. Systemic (>10 mg/day for >14 consecutive days) or therapy within 12 weeks prior to randomization.
  3. Use of renin inhibitors or medications significantly affecting creatinine levels within 4 weeks prior to randomization.
  4. Prior use of APRIL monoclonal antibodies, BAFF monoclonal antibodies, BAFF/APRIL dual-targeting agents, TACI/BCMA-targeting agents, etc.
  5. Concurrent nephrotic syndrome or hypoalbuminemia.
  6. Concurrent other chronic kidney diseases (e.g., diabetic nephropathy, membranous nephropathy).
  7. Rapidly progressive glomerulonephritis.
  8. Known or suspected immunodeficiency disorders.
  9. Poorly controlled blood pressure prior to randomization (systolic BP > 140 mmHg or diastolic BP > 90 mmHg).
  10. Poorly controlled type 2 diabetes mellitus ( > 8%).
  11. History of bone marrow, hematopoietic stem cell, or solid organ transplantation.
  12. Laboratory abnormalities during screening, such as /AST > 3.0 × , > 1.5 × ULN, etc.
  13. Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    IBI3034 group

    IBI3034,SC/IV,corresponding dose regimen according to study cohort

    Drug: IBI3034

  • Experimental
    Placebo Group

    Matching placebo of IBI3034, SC/IV ,corresponding dose regimen according to study design

    Drug: Placebo

  • Experimental
    Telitacicept (Part 2 only)

    Telitacicept , 240 mg subcutaneous injection once weekly

    Drug: Telitacicept

Interventions

  • DrugIBI3034

    IBI3034,SC/IV,corresponding dose regimen according to study design

  • DrugPlacebo

    Matching placebo of IBI3034,SC/ IV ,corresponding dose regimen according to study design

  • Telitacicept 240 mg SC QW × 24 doses (Weeks 0-24).

06

What researchers measure

Primary outcomes

  1. Safety: Incidence of adverse events (AEs) and serious adverse events (SAEs) following a single dose of IBI3034 in healthy participants(Part 1)

    Time frame: through study completion,an average of 169 days

  2. Safety: Incidence of AEs and SAEs following multiple doses of IBI3034 in participants with primary IgA nephropathy(Part 2)

    Time frame: through study completion,an average of 252 days

Secondary outcomes

  1. Pharmacodynamic (PD) Profile: Change from baseline in serum immunoglobulin levels(Part 1)

    Time frame: through study completion,an average of 169 days

  2. Exploratory Clinical Profile: Change from baseline in UPCR(Part2)

    Time frame: through study completion,an average of 252 days

  3. Pharmacodynamic (PD) Profile: Change from baseline in serum immunoglobulin levels (Part 2)

    Time frame: through study completion,an average of 252 days

  4. Exploratory Clinical Profile: Change from baseline in UACR (Part 2)

    Time frame: through study completion,an average of 252 days

  5. Exploratory Clinical Profile: Change from baseline in eGFR (Part 2)

    Time frame: through study completion,an average of 252 days

  6. Exploratory Clinical Profile: Change from baseline in hematuria(Part2)

    Time frame: through study completion,an average of 252 days

  7. Exploratory Clinical Profile: Change from baseline in serum albumin(Part2)

    Time frame: through study completion,an average of 252 days

  8. Exploratory Clinical Profile: Change from baseline in serum creatinine(Part2)

    Time frame: through study completion,an average of 252 days

  9. Exploratory Clinical Profile: Change from baseline in blood pressure (both systolic and diastolic)(Part2)

    Time frame: through study completion,an average of 252 days

  10. Maximum Concentration, Cmax (Part 1)

    Time frame: through study completion,an average of 57 days

  11. Time to Reach Peak Plasma Concentration (Tmax)(Part 1)

    Time frame: through study completion,an average of 57 days

  12. Apparent Clearance (CL/F) (Part 1)

    Time frame: through study completion,an average of 57 days

  13. Apparent Volume of Distribution (Vz/F) (Part 1)

    Time frame: through study completion,an average of 57 days

  14. Terminal Half-Life (T1/2) (Part 1)

    Time frame: through study completion,an average of 57 days

  15. Area Under the Concentration-Time Curve, AUC (Part 1)

    Time frame: through study completion,an average of 57 days

  16. Maximum Concentration, Cmax (Part 2)

    Time frame: through study completion,an average of 156 days

  17. Time to Reach Peak Plasma Concentration (Tmax)(Part 2)

    Time frame: through study completion,an average of 156 days

  18. Apparent Clearance (CL/F) (Part 2)

    Time frame: through study completion,an average of 156 days

  19. Apparent Volume of Distribution (Vz/F) (Part 2)

    Time frame: through study completion,an average of 156 days

  20. Terminal Half-Life (T1/2) (Part 2)

    Time frame: through study completion,an average of 156 days

  21. Area Under the Concentration-Time Curve, AUC (Part 2)

    Time frame: through study completion,an average of 156 days

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing Municipality 100009, China
    • hong zhao · Contacthongzh@bjmu.edu.cn · 13811123788
    • Xia Zhao, Dr. · Principal investigator
    • Hong Zhang, Dr. · Principal investigator
    • Jicheng Lv, Dr. · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.

Of 22 phase 1 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Oct 21, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Feb 28, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07886476
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Yating Liu
Contact
yangting.liu@innoventbio.com
0512-69566088

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion